Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.

By Danuta Radzik On October 30, 2025, two DDL shareholders, Danuta Radzik and Vanda Radzik, the Greenheart Movement and other ...

The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria treatment landscape is expected to undergo substantial transformation between ...

EXCLUSIVE: A Eurasian lynx has taken her first steps in her new UK home after being rescued from war-torn Ukraine.

The Securities and Exchange Commission (SEC) today released its Annual Report to Congress on the Dodd-Frank Whistleblower Program for Fiscal Year 2025, which detailed the millions of dollars awarded ...

West Virginia Gov. Patrick Morrisey spoke with WCHS-TV on Thursday regarding a number of topics.In the brief, one-on-one interview, Morrisey discussed his recen ...

The D.C. biotech also filed a shelf registration statement for $200 million, opening the door for it to raise that money over ...

Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-2.39 EPS, expectations were ...

Warby Parker Inc. (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 ...

Despite a 9% revenue increase, Vanda Pharmaceuticals Inc (VNDA) faces significant net losses and rising operating expenses.